SCHEMBL24549052

SCHEMBL24549052

Cn1c(Nc2ccc3cc[nH]c3c2)nc2ccc(C(F)(F)F)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.47
PIK3CD O00329 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
MTOR P42345 1/20 0.47
PIK3CG P48736 1/20 0.47
BRAF P15056 5/20 0.44
KDR P35968 4/20 0.44
RAF1 P04049 3/20 0.44
KIF11 P52732 2/20 0.40
EGFR P00533 1/20 0.40
SYK P43405 2/20 0.40
MET P08581 2/20 0.39
IDH1 O75874 2/20 0.39
MCHR1 Q99705 1/20 0.39
RET P07949 2/20 0.38
TEK Q02763 2/20 0.38
STK25 O00506 1/20 0.38
CIT O14578 1/20 0.38
EPHB6 O15197 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24549210 0.91 ESR1 (0.47) ESR1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL30763660 0.81 ESR1 (0.44) ESR1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL24549209 0.81 ESR1 (0.44) ESR1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL22803626 0.76 ESR1 (0.51) ESR1KIF11EGFRSYKIDH1
SCHEMBL22803779 0.75 ESR1 (0.52) ESR1KIF11EGFRSYKIDH1
SCHEMBL24549051 0.74 BRAF (0.41) BRAFKDRRAF1SYKMET
SCHEMBL29653810 0.74 BRAF (0.41) BRAFKDRRAF1SYKMET
SCHEMBL22803618 0.74 ESR1 (0.48) ESR1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL22803602 0.74 ESR1 (0.48) ESR1KIF11EGFRSYKMET
SCHEMBL22803950 0.73 ESR1 (0.50) ESR1MTORKDRKIF11EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2024-02-15 US disclosed
CN-117321048-A Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2023-12-29 CN disclosed
WO-2022133098-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 ESR1 1106/4885PIK3CD 830/4885PIK3CA 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.